

CALL FOR DATA PARTNERS IN ACUTE MYELOID LEUKEMIA

OCTOBER 2025



HARMONY
ALLIANCE FOUNDATION

The HARMONY Alliance Foundation is launching a **Call for Data Partners** aimed at collecting real-world data from AML patients treated with standard of care chemotherapies combined with targeted therapies.

Collecting real-world evidence to assess the treatment paradigm in acute myeloid leukemia

The HARMONY Alliance Foundation has succeeded in unifying a large number of datasets of genetically well-characterized AML patients receiving first line therapy, with homogeneous intensive treatments from trials and studies performed prior to the approval of first targeted therapies. However, since 2017, the treatment approach for AML has changed, with new therapies for patients harboring targetable mutations, and less intense therapies for unfit or younger patients, leading to better outcomes. Nonetheless, significant challenges remain, including high relapse rates, limited treatment options for older and frail patients, disease resistance to chemotherapy, and the lack of effective treatments for patients with high-risk mutations.

The overall goal of this data collection is to extend the centralized, harmonized, and curated HARMONY AML repository so that it can be used as historical control for:

- novel therapy approaches in a first line setting, mainly building on triple therapies, both combinations with intensive and less-intensive therapies, and
- the increasing number of novel approaches in the relapse/refractory setting.

Specific objectives of the call include making data available to researchers to assess the real-world impact of novel first-line therapies and salvage treatments—particularly targeted approaches, whose effects remain insufficiently defined—and to refine current treatment guidelines, risk classification schemes, and related frameworks.

Benefits for Data Partners

- * **Access** to the resulting database.
- * Possibility to **submit research questions** to the HARMONY Platform.
- * Access to **dashboards** to facilitate data visualization.
- * **Authorship rights** in any publication resulting from the use of your data.
- * **Potential funding and networking** opportunities.

Would you like to join?

[Fill out the Form and send your Expression of Interest](#)



Deadline for applications

14th November 2025

Lars Bullinger

Member of the HARMONY Alliance Board of Trustees

"The HARMONY Platform has become one of the strongest repositories for hematologic malignancy data and a valuable tool for the research community. Continuing to grow it will make it even stronger and more invaluable, with the power to advance the field more rapidly"

